We are international
Donate
TEXT SIZE   

Call the IMF Hotline. We are here for you. The IMF Office is open from 8:00AM - 5:00PM PST, Monday-Friday.

If you have a question, call the IMF InfoLine at (800) 452-CURE (800-452-2873) in the US and Canada. The InfoLine is open from 9:00 - 4:00 PT Monday - Friday. Elsewhere call (818) 487-7455. You can also contact us via the web.
IMF - Home Page
previous     next      view all

International Myeloma Foundation Hosts Congressional Briefing on Environmental Exposures
The International Myeloma Foundation is hosting a briefing to discuss research on links between exposure to environmental factors and multiple myeloma. Speakers at the briefing will discuss the latest research findings and share their personal stories about their experience with multiple myeloma. The audience will learn about multiple myeloma, opportunities to further research, potential environmental risk factors for multiple myeloma, and efforts among patient advocates, industry, researchers and policy makers to reduce the exposure to environmental toxins associated with myeloma.

Study Results Published Showing Advantages with Revlimid in Newly Diagnosed Myeloma
The New England Journal of Medicine published a study this week showing that Revlimid (lenalidomide) plus low-dose dexamethasone improves survival and other measures of efficacy compared to MPT (melphalan, prednisone, and thalidomide) in newly diagnosed multiple myeloma patients who are not eligible for a stem cell transplant. The study also showed that continuing use of Revlimid-dexamethasone instead of stopping after a fixed number of treatments provided further advantages in multiple measures

Living Well with Myeloma: Understanding the Immune System and Lab Values in Myeloma teleconference
The IMF's popular Living Well with Myeloma teleconference series returns on August 28th, with "Understanding the Immune System and Lab Values in Myeloma." The discussion and Q&A will be led by IMF Nurse Leadership Board member Ann McNeill, RN, MSN, APRN-C, Multiple Myeloma Division, Hackensack University Medical Center. The free teleconference will be held on Thursday, August 28th at 7 pm ET/ 4 pm PT.

ASCO Post Features Profile of Myeloma Patient Advocate Mike Katz
IMF board member Mike Katz is profiled in the latest issue of the ASCO Post, a publication of the American Society of Clinical Oncology. Writer Jo Cavallo talked with Katz about his advocacy for myeloma patients and how he has helped to alter the standard of care. “I’ve always chosen to live my life as if I didn’t have cancer,” Katz said. “I just face forward and try to do everything I want to do, working around symptoms and treatment side effects.”

More on Measles Virotherapy for Myeloma
Last week, the popular radio show Science Friday broadcast on National Public Radio explored the exciting science around cancer virotherapy. Guest Dr. Stephen Russell of the Mayo Clinic shared his experience treating myeloma patients with massive doses of the measles virus, which Dr. Durie has blogged about in the past. eek, the popular radio show Science Friday broadcast on National Public Radio explored the exciting science around cancer virotherapy. Guest Dr. Stephen Russell of the Mayo Clinic shared his experience treating myeloma patients with massive doses of the measles virus, which Dr. Durie has blogged about in the past.

MRD Testing: Have We Found the Method We Need?
Two types of tests are currently in development to measure minimal residual disease (MRD) in myeloma patients: a sophisticated new flow cytometry test and a molecular test. In his blog this week, IMF Chairman Dr. Brian Durie examines the differences between the two and explains why, in his opinion, the flow cytometry test is superior.

FDA Approves Use of Velcade for Retreatment of Myeloma
The US FDA has approved the use of Velcade for retreatment of myeloma patients who have previously responded to Velcade and have relapsed at least six months after their prior treatment. The expanded approval was granted based on data from a phase II clinical trial. This approval includes IV and subcutaneous forms of Velcade.

Cancer Cases Among 9/11 Early Responders Continue to Grow
More cancer cases are being reported among 9/11 rescuers and responders, with more than 2,500 people with cancer now included in World Trade Center health programs. Myeloma is covered under the 9/11 Victim Compensation Fund, and studies have shown that 9/11 workers have gotten myeloma at a higher rate than expected in the normal population. Research has also shown a relationship between myeloma and exposure to carcinogens located at the World Trade Center site. IMF Chairman Dr. Brian Durie has written extensively on myeloma and toxins, and in his blog this week, he examines this troubling growth in cases.

#AskDrDurie: Is it okay to take vitamin B12 on the same day as Velcade?

In this episode of #AskDrDurie, Dr. Brian Durie of the IMF answers a myeloma patient’s question about taking a supplement like vitamin B12 on the same day as Velcade.


Summer 2014 Edition of Myeloma Today

Articles include:

  • Key Questions 2014: Highlights from the 5th Annual IMWG Summit
  • Highlights from the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO)
  • Living Well With Myeloma:  Expert Advice on Pain Management


previous     next      view all